Comorbidities, Treatment and Ensuing Survival in Men with Prostate Cancer
- 257 Downloads
Comorbidity is poorly integrated into prostate cancer decision making.
We sought to characterize treatment type and subsequent survival for men with no more than a single comorbid condition.
Design and Participants
We conducted a retrospective study of 1,031 veterans with non-metastatic prostate cancer diagnosed in 1997–2004 at the Greater Los Angeles and Long Beach Veterans Affairs Medical Centers and followed until 2010. We used multivariate analyses to determine probabilities and relative risks of undergoing treatment for each health state and competing-risks regression analyses to model non-prostate cancer mortality.
Compared with subjects without any comorbid conditions, only men with moderate–severe chronic obstructive pulmonary disease were less likely to receive definitive treatment for their prostate cancer (RR 0.74; 95% CI 0.44–0.99). Men with all other individual comorbidities were equally likely as men without comorbidity to receive definitive treatment. Compared with men without any comorbidities, a higher hazard rate for non-prostate cancer mortality was identified among men with diabetes without end-organ damage (HR 2.32; 95% CI 1.32–4.08), peripheral vascular disease (HR 2.77; 95% CI 1.14–6.73), moderate-severe chronic obstructive pulmonary disease (HR 5.46; 95% CI 2.68–11.12), diabetes with end-organ damage (HR 4.27; 95% CI 1.64–11.10), those in need of a mobility device (HR 3.29; 95% CI 1.87–5.80), and men with history of alcoholism (HR 1.77; 95% CI 1.07–2.93).
Men with comorbid conditions and health states that portend poor prognoses are nonetheless aggressively treated for their prostate cancer. Advancing age modulates this effect.
KEY WORDSprostatic neoplasms comorbidity outcome assessment survival treatment mismatch
Dr. Chamie and Lorna Kwan had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the analysis.
Conflicts of Interest
This work was supported by the American Cancer Society (117496-PF-09-147-01-CPHPS (Principal Investigator: KC)); Ruth L. Kirschstein National Research Service Award Extramural (1 F32 CA144461-01 (Principal Investigator: KC)); Jonsson Comprehensive Cancer Center Seed Grant (Principal Investigator: MSL)); and National Institute of Diabetes and Digestive and Kidney Diseases (N01-DK-1-2460 (Principal investigator: M.S.L.))
No financial disclosures to report.
- 4.Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM, et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 2005;23(12):2772–80.PubMedCrossRefGoogle Scholar
- 10.May S, Hosmer DW. Hosmer and Lemeshow type goodness-of-fit statistics for the Cox proportional hazards model. In: Balakrishnana N, Rao CR, eds. Advances in Survival Analysis: Handbook of Statistics Vol 23. Amsterdam: Elsevier, North-Holland; 2004:383–394.Google Scholar